Oregon is currently home to 1217 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prevalence of Antibodies and Cytokines in Participants with Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
02/04/2025
Locations: Home-based telemedicine, Salem, Oregon
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.
NCT06524375
Recruiting
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Asante Rogue Regional Medical Center, Medford, Oregon
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Implementation of Problem-Solving Treatment in Community Health Centers (PST-Aid)
NCT06494384
Recruiting
Although evidence-based clinical interventions (CI) are a preferred treatment option for patients with depression, CIs are rarely available in community primary care settings. When available, CIs are often delivered with poor fidelity and abandoned by practitioners during the initial months post-training. Identifying effective implementation strategies to support the adoption, reach, and sustained use with fidelity of these CIs could enhance the effectiveness of primary care-based treatment of d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: OCHIN, Inc., Portland, Oregon
Conditions: Depression
Register for Updates
K-ORCA: Testing a Decision Support Tool and Group Process for Selecting Interventions
NCT06375551
Recruiting
This proposal responds to NIMH Objective 4.2.c to develop "decision-support tools and technologies that increase the effectiveness and continuous improvement of mental health interventions" by leveraging the Family First Prevention Services Act (FFPSA) policy opportunity. First, a web-based platform to host (a) a decision-support tool and (b) automated facilitation for group decisions with the tool will be developed with state partners' feedback. Next, decision makers leading their states' FFPSA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Chestnut Health Systems, Eugene, Oregon
Conditions: Child Abuse, Decision Making, Child Welfare, Decision Making, Shared, Decision Support Technique, Social Facilitation, Implementation Science, Policy, Organizations, Consensus, Mental Health, Family
Register for Updates
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550 (study 1305-0014 or 1305-0023). The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until sympto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Oregon Clinic, Portland, Oregon
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/04/2025
Locations: Bend Memorial Clinic/Summit Medical Group - Eastside, Bend, Oregon
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Asante Rogue Regional Medical Center, Medford, Oregon
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Register for Updates
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Research Site 1133-0, Eugene, Oregon
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01).
NCT06012435
Recruiting
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133
Recruiting
This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-EGFRd2 should be given to participants. Part C will use the dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Register for Updates
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414
Recruiting
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androg... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
02/04/2025
Locations: Oregon Urology Institute, Springfield, Oregon
Conditions: Oligometastatic Prostate Cancer (OMPC)
Register for Updates
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05848284
Recruiting
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Oregon Health and Science Unversity, Portland, Oregon
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Register for Updates